Current Share Price and Basic Status
- Abpro Bio share price: around KRW 357 (closing price on 11/19, intraday range KRW 350–428)
- 52-week range: KRW 178–534
- Market cap: around KRW 101.6 billion (KRW 101,634 million; about 28.5 million shares outstanding)
→ It’s a low-priced (“penny”) stock, and over the past year it has swung up and down by almost 3x, making it a highly volatile name.
- 2025-11-05: Hit the upper limit early in the session (+29.95%, KRW 243). The trading value surged into the KRW 10 billion range.
- 11-12, 11-13: Appeared consecutively among the top KOSDAQ stocks by short-selling volume
- 11-13: The exchange requested an inquiry disclosure due to “significant price and trading fluctuations.” The company responded: “There is no important information that needs to be disclosed separately.”
In other words, the company itself effectively acknowledged that the recent sharp rises and drops were driven more by supply-demand and investor sentiment than by any clear new fundamental catalyst.
Company and Business Structure
(The name says “Bio,” but in substance it’s a machinery company.)
- Listed on the KOSDAQ in the Machinery & Equipment sector
- Head office in Dalseong-gun, Daegu, founded in 2004, listed in 2015
- As of 2024, revenue breakdown:
- Machining centers (machine tools): over 80%
- The rest: ATC & spindle products, semiconductor equipment, etc.
From an earnings standpoint, it still has the clear profile of a “machine tool and semiconductor equipment company.”
However, it also functions like a holding company, owning several bio affiliates 100%:
- Abpro Bio International Inc. – U.S.-based developer of bispecific antibody drugs
- ABpro Pharma, Saint Pharm – pharmaceutical R&D and wholesale
- ANH – semiconductor equipment manufacturing
→ The “U.S. affiliate NASDAQ listing / bio momentum” story circulating in the market is basically a theme derived from these subsidiaries and affiliates.
In 2024, the domestic share price spiked and hit the upper limit multiple times when news came out. It revealed that the U.S. affiliate had received approval for a NASDAQ SPAC merger and listing.
Earnings and Financial Condition
(Key points: persistent losses + issues with recovering funds lent to subsidiaries)
1) Profitability
- 2025-06 quarter (announced 8/14)
- Revenue: about KRW 9.1 billion
- EPS: –KRW 155.86 (loss of around KRW 150 per share)
- EPS (TTM): –KRW 219.22 (sum over the past 12 months)
- PER: “–” based on the latest fiscal year (cannot be calculated due to losses)
- PBR: about 0.92x (trading at a slight discount to book value)
→ The company continues to generate operating revenue, but profitability is almost non-existent.
2) Funds Lent to Subsidiaries and Impairment (Bad Debt) Issues
- For domestic subsidiary ABpro Pharma, loans of KRW 2.2 billion were fully provisioned as bad debt.
- For U.S. affiliate Abpro Bio International, the company also set up hundreds of billions of KRW in provisions against loans and accrued income.
→ Media reports characterize these as “funds that are difficult to recover.”
Effectively, the company is acknowledging that a large portion of the money it lent to its subsidiaries and affiliates may not be recoverable.
→ This implies that book assets (shareholders’ equity) may continue to be written down going forward.
3) Capital and CB (Convertible Bond) History
- Over the past several years, capital has been increased multiple times through the conversion of domestic convertible bonds (CBs).
- Between 2022 and 2023, CB conversions led to the listing of several million shares at a time.
→ From the perspective of existing shareholders, this means constant dilution over time.
Although the company has not yet entered formal delisting procedures, the combination of:
- ongoing provisions and losses → shrinking equity, and
- additional CBs and equity offerings (rights issues) → repeated dilution for funding
means that, in the long term, the stock carries both “watchlist/delisting risk” and “dilution risk” at the same time.
Recent Issues and Flow of Funds
1) Upper Limits and Spike Patterns
- 2025-11-05: Hit the upper limit (+29.95%, KRW 243), marking a second straight day of sharp gains. It rose the previous day as well.
- There have also been multiple upper-limit or sharp rally days in the past around news of the U.S. affiliate’s NASDAQ merger.
2) Short-Selling and Foreign Flow
- 11-11, 11-13: Featured among the top KOSDAQ stocks by short-selling volume.
- 11-13: Also ranked among the top 20 KOSDAQ names by net foreign buying.
→ This is a textbook example of a “trading stock” where short-selling and short-term foreign trading are very active.
3) Inquiry Disclosure on Significant Market Movement
- 2025-11-12: The exchange requested an inquiry disclosure citing “significant market volatility.”
- 11-13: The company replied: “There is no important information that needs to be disclosed separately.”
(In other words, there is no particular new positive or negative catalyst.)
4) Control Disputes and Shareholder Activism
- Since September 2025, there have been numerous disclosures regarding litigation over control. There were also requests to convene extraordinary shareholders’ meetings and similar shareholder–management conflicts.
- According to FnGuide, the combined stake of the largest shareholder and related parties is only 3.97%. This means
the governance structure is unstable and outside players / activist shareholders can easily get involved.
So overall:
Rather than rising on genuine fundamental improvement,
the stock price tends to swing around on control disputes + the U.S. affiliate story + supply-demand (retail/foreign/short-selling).
Outlook – How Should This Be Viewed?
1) Short-Term View (Next Few Weeks to 1 Year)
Positive Factors
- The stock often sees explosions in trading volume and value.
It frequently shows short-term “waves” as a theme/trading stock. - Whenever there is news about the U.S. affiliate’s NASDAQ listing, or
developments in the control dispute (extraordinary shareholders’ meetings, court rulings, etc.),
the share price can show large swings.
Negative Factors / Risks
- If the stock were to spike again even after the company has explicitly stated
“there is no important information to disclose,” that would strongly suggest a market
driven purely by supply-demand and sentiment games. - Because this is a stock with active short-selling and short-term foreign trading,
sharp whipsaws both up and down (shakeouts, pump-and-dump type moves) can be severe. - Given the weak financial structure and continuing provisions and losses,
there is always the risk of additional CB issuance, capital increases, and further dilution.
👉 Some traders may view it as a high-risk short-term trading vehicle to “ride the waves,”
but almost nobody would see it as a stable, high-quality stock.
2) Medium- to Long-Term View (3+ Years) – What Conditions Would Need to Be Met?
(1) Fundamental Improvement Scenario (Positive)
- The core machine tool and semiconductor equipment business would need to show sustained return to profitability and margin improvement.
- The U.S. and domestic bio affiliates would need to start generating real cash flows in the form of revenue, licenses, or royalties. Only then will the “subsidiary NASDAQ listing story” translate into real earnings, dividends, and equity value.
- The issues around bad debt provisions and fund recovery would have to be resolved. Additionally, the financial structure would need to be stabilized without concerns over capital erosion.
- The disputes over control would have to be settled, bringing governance stability.
→ If all of this really happens, then at the current market cap level (around KRW 100 billion) there would be room for re-rating.
(2) Negative Scenario
- If margins remain weak in the core machine tool business and the bio affiliates continue to incur additional costs for a long time instead of generating profits;
- If failure to recover loans to affiliates becomes reality and asset values keep shrinking,
→ risk of capital erosion and watchlist/delisting grows. - If the company keeps plugging funding gaps with CBs and equity offerings whenever needed,
existing shareholders will suffer ongoing dilution. Consequently, the stock could be stuck in a long-term trading range or downtrend.
Summary from an Individual Investor’s Perspective
This is a high-risk small-cap whose earnings and financials are weak,
and whose price swings sharply on themes, events, and supply-demand, rather than solid fundamentals.
So:
- It is not the kind of stock you typically hold as a long-term (3–5+ year) investment.
Rather, it fits into the category of a high-risk, short-term trading stock used purely to ride waves.
If you do decide to approach it:
- Limit it to a very small portion of your portfolio (e.g., 5% or less),
- Set clear stop-loss and take-profit rules in advance
(for example, –15% stop-loss, +30% partial profit-taking, etc.), and - Treat it as an area where you trade based on trading value and news flow.
Not on “fundamental improvement of the business.”
It is definitely not the kind of stock you “go all-in” on.
With accumulated losses, bad debt issues, control disputes, and a history of CB-related dilution all bundled together, the risk–reward balance is highly uncertain.